Screener
Supernus Pharmaceuticals SUPN Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $40.9M.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
FAQ
- What is Supernus Pharmaceuticals's total debt?
- Supernus Pharmaceuticals (SUPN) reported total debt of $40.9M in Q1 2026.
- How has Supernus Pharmaceuticals's total debt changed year-over-year?
- Supernus Pharmaceuticals's total debt increased by 26.6% year-over-year, from $32.31M to $40.9M.
- What is the long-term trend for Supernus Pharmaceuticals's total debt?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's total debt has grown at a -7.4% compound annual growth rate (CAGR), from $60.1M to $40.98M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about Supernus Pharmaceuticals's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude